SK Pharmteco has announced a $6.1 million investment to expand its Rancho Cordova, California, facility with new lab and kilo-scale capabilities for solid-phase peptide synthesis and purification.
Abzena, an end-to-end integrated CDMO for complex biologics and bioconjugates, announced that Orion has obtained an exclusive focused commercial license to one of Abzena’s mAbs..
Following the acquisition of MCE Pharma Brenntag is building a unique position in both traditional pharma and biopharma.
Investments will bolster clinical and commercial capacity in US and Europe facilities for injectable and oral solid dose packaging, and sterile filling.
Cambrex announced a $120 million investment to expand its API manufacturing capacity at its Charles City, Iowa, facility by 40%.
The investment will focus on developing gelatin and HPMC facilities, creating over 200 new jobs, and strengthening ACG’s 25-year presence in the US, with operations expected to begin in early 2027.
Roquette has inaugurated a new Pharmaceutical Innovation Center in Brazil to support advanced research and development in the region’s pharmaceutical sector.
Part 3: Seven Theses for successful Digitalization in Pharma
Harke Pharma has completed the acquisition of a highly acclaimed nutraceutical Memory Complex originally developed by Green Bioactives, UK.
Part 2: Digital transformation - 10 Years after the Start of Pharma 4.0
Fujifilm Biotechnologies has opened one of North America's largest commercial-scale cell culture biomanufacturing sites in Holly Springs, North Carolina, US.
Part 1: Building a Business Case for Pharma 4.0
Symeres has appointed Gabriella Gentile as Chief Operating Officer to lead global operations and drive transatlantic growth, leveraging her extensive experience in the pharmaceutical and biotech sectors.
New state-of-the-art active pharmaceutical ingredient (API) facility in North Chicago will manufacture immunology, oncology, and neuroscience medicines.
Join us for a dynamic virtual event where science meets strategy.
Dinamiqs, a Siegfried company specialized in viral vector design and manufacturing, inaugurated its new cGMP manufacturing facility.
Lilly plans to build a new $6.5 billion facility to manufacture active pharmaceutical ingredients in Houston, Texas.
Pfizer to acquire Metsera, a New York, NY-based clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and cardiometabolic diseases.
Prange Pharma is taking over a production site from MSD Animal Health in Aprilia, Italy. A new center for contract manufacturing in the field of animal health products is to be established there.
Acquisition supports Roche’s strategy as it enhances the company’s portfolio in cardiovascular, renal, and metabolic diseases (CVRM) and offers optionality for future combination development.
Includes $1.2 billion in manufacturing facilities, AI, and advanced digital technologies, creating hundreds of highly skilled US jobs.
The pharmaceutical industry has faced significant margin pressures due to rising energy costs, inflation, and geopolitical disruptions.
Amid global uncertainty, Bayer Pharma, led by Stefan Oelrich, pursues strategic transformation to boost resilience, drive innovation, and secure sustainable growth in a changing healthcare landscape.
Asahi Kasei Life Science emerges as a new growth driver, uniting bioprocess solutions, CRO, and CDMO services to shape the future of healthcare under President Ken Shinomiya’s leadership.
LGC Group has inaugurated a CAD$100 million (€61.5 million) Organic Chemistry Synthesis Centre of Excellence in Vaughan, Canada.
Novo Nordisk announced a global workforce reduction of approximately 9,000 positions to streamline operations and reinvest DKK 8 billion (€1 billion) in growth opportunities for diabetes and obesity treatments.
How pharma & biotech company transformed warehouse capacity planning for strategic growth
CRDMO Symeres has acquired DGr Pharma, expanding its capabilities with DGr Pharma’s regulatory and consultancy expertise to provide more comprehensive drug development services.
New Bay Area building marks significant progress as part of Gilead's $32 billion US investment.
The $700 million project is part of Genentech and Roche’s $50 billion investment in U.S. manufacturing, infrastructure and R&D
Gilgamesh's lead asset, bretisilocin (GM-2505), is a potential best-in-class psychedelic compound currently in Phase 2 development for the treatment of major depressive disorder (MDD).
AstraZeneca recently announced $50 billion of investment in the US by 2030. This investment is expected to create tens of thousands of new, highly skilled jobs nationwide.
Vetter broke ground for the start of construction of its new clinical site in Des Plaines, Illinois, US on June 26.
IMCD, a global partner for the distribution and formulation of speciality chemicals and ingredients, has acquired Trichem, an Indian pharmaceutical supplier.
Mabion, a biotech-focused CDMO offering end-to-end services, has announced the launch of a €500,000 oncology services contest at BIO International Convention 2025.
